AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19
Shots:
- The P-III D8110C00001 study involves assessing AZD1222 vs PBO in 32-449 participants in a ratio (2:1) aged ≥18yrs. across 88 trial centers in the US- Peru and Chile to prevent COVID-19. his primary efficacy analysis included the accrual of 190 symptomatic cases of COVID-19 from total participants
- The study showed 76% efficacy against symptomatic COVID-19- 85% efficacy in aged ≥65yrs. as its 1EPs and showed 100% efficacy against severe disease and hospitalization in 2EPs. The vaccine was well tolerated with no safety concerns
- The company will submit EUA to US FDA and also submit the primary analysis for peer-reviewed publication in the coming weeks
Ref: AstraZeneca | Image: Mint
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com